Recordati S.p.A. / Sanofi SA

Cold Agglutinin Disease (CAD)

8K US cases/yr · $150M Enjaymo expected FY2025 revenue (>EUR150M, single-asset orphan market) · 300 Enjaymo peak annual sales potential guidance (EUR MM, upper bound)

Disease Overview

Cold agglutinin disease (CAD) is a rare, chronic autoimmune hemolytic anemia driven by IgM autoantibodies that bind red blood cell surface antigens at low temperatures, activating the classical complement pathway (C1s -> C4 -> C3 -> MAC) and triggering predominantly extravascular hemolysis in the liver. A published 2016-2023 US administrative-claims analysis (PLOS One, 2025) found a CAD point prevalence of 1.6 to 3.3 per 100,000 persons, with annual incidence of 0.6 to 1.2 per 100,000 - corresponding to roughly 5,000-11,000 prevalent US patients and 2,000-4,000 new cases per year, concentrated in adults 40-80 (median onset ~65) with a female predominance. Clinical burden includes chronic fatigue, exercise intolerance, transfusion dependence, Raynaud-like acrocyanosis, and a documented increase in thrombotic events and mortality versus matched controls. Before Enjaymo's Feb-2022 FDA approval, management relied on cold avoidance, off-label rituximab-based B-cell depletion, corticosteroids, and supportive transfusions - none of which specifically addressed classical-pathway complement activation. Enjaymo is the only disease-targeted therapy approved in the US, EU, and Japan, making CAD a classic rare-disease monopoly asset that Recordati can run with standard orphan-franchise economics.

Competitive Landscape

CAD therapy is a single-asset orphan market dominated by Enjaymo (sutimlimab, now Recordati), a humanized anti-C1s monoclonal antibody that selectively inhibits the classical complement pathway at the proximal C1s step - the only FDA/EMA/PMDA-approved disease-targeted therapy. Off-label and supportive use still includes rituximab (Rituxan/Truxima, Roche/Teva biosimilars) as B-cell-depleting anti-CD20 therapy, often combined with bendamustine or fludarabine, and transfusion plus cold-avoidance. Broader classical-pathway inhibition contenders include pegcetacoplan (Empaveli, Apellis/Sobi), a C3 inhibitor approved for PNH and C3G with CAD investigational interest, and iptacopan (Fabhalta, Novartis), an oral factor B inhibitor approved for PNH/IgAN/C3G also exploring adjacent hemolytic anemias. Terminal-pathway C5 inhibitors eculizumab (Soliris, Alexion/AstraZeneca) and ravulizumab (Ultomiris, Alexion/AstraZeneca) are not indicated in CAD because hemolysis is predominantly extravascular. The competitive moat for Recordati is mechanism specificity at C1s plus first-mover label, with pipeline encroachment most likely from Apellis/Sobi or Novartis if they pursue CAD-specific development.